Table 1.
Patient demographic, clinical and tumour characteristics.
| N (%) | 170 (100) |
|---|---|
| Sex | |
| Male | 78 (46) |
| Female | 92 (54) |
| Age | |
| Minimum | 25 |
| Median | 70 |
| Maximum | 92 |
| ECOG performance status | |
| 0 | 50 (34) |
| 1 | 54 (36.7) |
| 2 | 22 (15) |
| 3 | 15 (10.2) |
| 4 | 6 (4.1) |
| Cancer diagnosis | |
| Breast cancer | 40 (23.7) |
| Gastrointestinal tumours | 38 (22.5) |
| Genitourinary tract tumours | 22 (13) |
| Lung cancer | 18 (10.6) |
| Haematologic malignancies | 14 (8.3) |
| Melanoma | 9 (5.3) |
| Gynaecologic cancers | 7 (4.1) |
| Head and neck | 5 (3) |
| Other | 17 (10) |
| Stage | |
| I | 32 (19.2) |
| II | 15 (9.1) |
| III | 21 (12.6) |
| IV | 99 (59.3) |
| Documented lung metastases | |
| Yes | 27 (16) |
| No | 143 (84) |
| Smoking status | |
| Smoker | 27 (15.9) |
| Former smoker | 37 (21.7) |
| Non-smoker | 89 (52.3) |
| NA | 17 (10) |
| Comorbidities | |
| Hypertension | 72 (42.4) |
| Cardiac comorbidities | 51 (30) |
| Diabetes | 30 (17.6) |
| Obesity | 23 (13.5) |
| Pulmonary comorbidities | 16 (9.4) |
| Autoimmune disorders | 12 (7.1) |
| Chronic renal failure | 12 (7.1) |
| Other | 70 (41.2) |
| Presence of at least 1 comorbidities | 135 (79.4) |
| Presence of 2 or more comorbidities | 85 (50) |
| Active anticancer therapy∗ | |
| Any | 89 (52.4) |
| Chemotherapy | 46 (27) |
| Targeted therapy | 24 (14) |
| Endocrine therapy | 19 (11.2) |
| Immunotherapy | 9 (5.3) |
ECOG, Eastern Cooperative Oncology Group.
∗
Multiple choice allowed.